C000107269 Performance — Voya Emerging Markets Index Portfolio, Class S
Data updated: 2025-05-22
C000107269 returned +7.65% over one year to Mar 2025. Annualised returns are +1.04% over 3 years and +1.47% over 5 years. Against its Emerging Markets Equity category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $103, against $105 for the category, and to $108 over one year, against $106. Volatility over the past three years was 17.81% a year. In the 12 months to Mar 2025 the fund lost a net $13.9M, and assets reached $91.56M.
C000107269 Growth of $100
What $100 invested in Voya Emerging Markets Index Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | C000107269 | Category average |
|---|---|---|
| 1 year (Apr 2024 – Mar 2025) | $108 | $106 |
| 3 years (Apr 2022 – Mar 2025) | $103 | $105 |
| 5 years (Apr 2020 – Mar 2025) | $108 | $149 |
| Since data start (Jul 2019 – Mar 2025) | $107 | $124 |
C000107269 Trailing Returns
Total returns to Mar 2025, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | +7.65% |
| 3 years (annualised) | +1.04% |
| 5 years (annualised) | +1.47% |
C000107269 Annual Returns
Calendar-year total returns of Voya Emerging Markets Index Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2025 (Jan–Mar) | +3.98% |
| 2024 | +5.80% |
| 2023 | +9.38% |
| 2022 | −20.51% |
| 2021 | −3.91% |
| 2020 | +16.75% |
| 2019 (Jul–Dec) | +0.07% |
C000107269 Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +1.8% | +0.8% | +1.4% | — | — | — | — | — | — | — | — | — |
| 2024 | −4.6% | +4.6% | +2.4% | −0.2% | +1.6% | +3.1% | +0.9% | +0.9% | +5.8% | −4.1% | −2.7% | −1.5% |
| 2023 | +8.5% | −7.1% | +3.2% | −0.9% | −2.3% | +4.1% | +5.6% | −6.3% | −2.7% | −3.4% | +7.9% | +3.8% |
| 2022 | −0.4% | −4.2% | −2.9% | −5.7% | +0.9% | −5.9% | −0.5% | −0.5% | −11.8% | −2.7% | +15.9% | −2.8% |
| 2021 | +2.9% | +1.0% | −1.2% | +1.5% | +1.5% | +1.2% | −6.8% | +2.2% | −4.1% | +1.0% | −4.3% | +1.7% |
| 2020 | −0.1% | 0.0% | −0.2% | +0.1% | 0.0% | +0.1% | +0.1% | 0.0% | 0.0% | 0.0% | +9.0% | +7.1% |
| 2019 | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +0.1% |
C000107269 Risk
Risk measures from monthly returns over Apr 2022 – Mar 2025.
- 3-year volatility (annualised): 17.81%
- 3-year Sharpe ratio: -0.19 (vs 4.5% risk-free rate)
- Best month: +15.89% (Nov 2022)
- Worst month: −11.78% (Sep 2022)
C000107269 Fund Flows
Monthly money in and out of Voya Emerging Markets Index Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$13.9M
- 12-month gross sales (incl. reinvestments): $13.2M
- Sales ÷ redemptions: 0.49×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Mar 2025 | $26K | $6.5M | −$6.4M |
| Feb 2025 | $74K | $1.2M | −$1.2M |
| Jan 2025 | $573K | $1.5M | −$922K |
| Dec 2024 | $5.7M | $1.4M | $4.3M |
| Nov 2024 | $8K | $1.4M | −$1.4M |
| Oct 2024 | $332K | $2.6M | −$2.3M |
| Sep 2024 | $42K | $1.3M | −$1.3M |
| Aug 2024 | $22K | $1.5M | −$1.5M |
| Jul 2024 | $28K | $1.9M | −$1.9M |
| Jun 2024 | $510K | $4.2M | −$3.6M |
| May 2024 | $5.8M | $1.6M | $4.2M |
| Apr 2024 | $78K | $1.9M | −$1.9M |
C000107269 Assets Under Management
Net assets of Voya Emerging Markets Index Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2025-03-31 | $91.56M |
| 2024-12-31 | $96.16M |
| 2024-09-30 | $103.52M |
| 2024-06-30 | $100.71M |
| 2024-03-31 | $103.24M |
| 2023-12-31 | $95.48M |
| 2023-09-30 | $94.86M |
| 2023-06-30 | $98.96M |
| 2023-03-31 | $596.62M |
| 2022-12-30 | $650.25M |
| 2022-09-30 | $569.91M |
| 2022-06-30 | $682.75M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.